Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$30.1 billion.

  • Addex Therapeutics' Share-based Compensation rose 9294.93% to -$30.1 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $3.6 billion, marking a year-over-year increase of 10035.25%. This contributed to the annual value of $571720.0 for FY2024, which is 7138.59% down from last year.
  • As of Q2 2025, Addex Therapeutics' Share-based Compensation stood at -$30.1 billion, which was up 9294.93% from $27.7 billion recorded in Q1 2025.
  • Addex Therapeutics' 5-year Share-based Compensation high stood at $1025.2 billion for Q2 2023, and its period low was -$1584.2 billion during Q4 2023.
  • Its 4-year average for Share-based Compensation is $523.8 million, with a median of $820318.9 in 2022.
  • Over the last 5 years, Addex Therapeutics' Share-based Compensation had its largest YoY gain of 14977254208.53% in 2023, and its largest YoY loss of 22287866601.02% in 2023.
  • Quarter analysis of 4 years shows Addex Therapeutics' Share-based Compensation stood at $710802.0 in 2022, then tumbled by 222878666.01% to -$1584.2 billion in 2023, then soared by 66.01% to -$538.5 billion in 2024, then soared by 94.41% to -$30.1 billion in 2025.
  • Its last three reported values are -$30.1 billion in Q2 2025, $27.7 billion for Q1 2025, and -$538.5 billion during Q4 2024.